Wealthfront Advisers LLC Cuts Stock Position in Stryker Corporation $SYK

Wealthfront Advisers LLC cut its holdings in shares of Stryker Corporation (NYSE:SYK) by 25.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,818 shares of the medical technology company’s stock after selling 12,937 shares during the quarter. Wealthfront Advisers LLC’s holdings in Stryker were worth $11,907,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in SYK. Strategic Wealth Advisors LLC boosted its stake in shares of Stryker by 50.4% in the second quarter. Strategic Wealth Advisors LLC now owns 197 shares of the medical technology company’s stock worth $62,000 after acquiring an additional 66 shares during the period. First National Bank of Omaha raised its stake in Stryker by 61.4% during the 2nd quarter. First National Bank of Omaha now owns 8,129 shares of the medical technology company’s stock valued at $2,639,000 after purchasing an additional 3,092 shares during the period. Navigoe LLC bought a new stake in Stryker during the 2nd quarter valued at approximately $34,000. Citizens Financial Group Inc. RI lifted its holdings in Stryker by 3.8% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 67,075 shares of the medical technology company’s stock worth $21,118,000 after purchasing an additional 2,464 shares in the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc lifted its holdings in Stryker by 6.2% in the 2nd quarter. Texas Capital Bank Wealth Management Services Inc now owns 2,291 shares of the medical technology company’s stock worth $721,000 after purchasing an additional 134 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. BTIG Research cut their price objective on shares of Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a report on Friday, May 1st. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Robert W. Baird set a $385.00 target price on shares of Stryker in a research note on Friday, May 1st. Finally, Piper Sandler reduced their price target on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Price Performance

Shares of Stryker stock opened at $331.96 on Wednesday. The firm has a market cap of $127.33 billion, a PE ratio of 34.40, a PEG ratio of 2.16 and a beta of 0.76. The stock has a 50 day moving average of $325.56 and a 200 day moving average of $333.05. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Insider Activity at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 315,370 shares of company stock valued at $98,463,501 over the last 90 days. 4.60% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.